|01-12-2018 09:46 AM CET - Health & Medicine||
Intra-Uterine Contraceptive Devices Market worth 4,851.2 Million USD Globally by Top Players Analysis, Industry Growth Rate, Size, Product Type and Forecast till 2024
Press release from: Data Bridge Market Research
According to the new research report “Global Intra-Uterine Contraceptive Devices, By Product Type (Hormonal IUCD, Copper IUCD), By End-User (Hospitals, Gynecology Clinics, Community Healthcare), By Geography (North America, Europe, Asia-Pacific, South America, Rest of the World)” – Forecast to 2024
Global Intra-Uterine Contraceptive Devices Market report estimated to reach USD 4,851.2 million by 2024 from USD 3,684.1 million in 2016, at a CAGR of 3.5% in the forecast period 2017 to 2024.
Key Drivers of Global Intra-Uterine Contraceptive Devices Market:
Some of the major factors driving the market for Intra-Uterine Contraceptive Devices (IUCD), such as growing awareness of contraceptive, increased rate of unplanned pregnancies, rising number of initiatives undertaken by the private firms, technological advancements and favourable insurance for IUCD’s.
• The growing rate of unintended pregnancies has aided the increase in the adoption of contraceptive methods which is expected to drive the growth of the IUCD market.
• The rising number of initiatives to promote the use of intra uterine contraceptive devices acts as a significant driver for this market.
• Growing awareness of contraceptive one of the factors contributing to the growth of the market in Europe.
Request for Free Sample Report Visit @ databridgemarketresearch.com/request-a-sample/?dbmr=globa...
Global Intra-Uterine Contraceptive Devices Industry is highly concentrated to a few big players and rest to local players who cater to domestic markets only. Bayer AG dominated the IUCD devices market accounting for a highest market share in 2016, followed by Teva Pharmaceuticals Industries Ltd., and Mona Lisa N.V. Some of the other players in this market include DKT International, Egemen International, Melbea AG, Ocon Medical Ltd., Pregna International Limited, Medical Engineering Corporation SA and, SMB Corporation and Meril Life Sciences Pvt. Ltd., Medu Scientific Ltd, China RH Contraceptives Co., Ltd, Sanghai Jolly Medical Education Co., Ltd, Bernstein Leibhard LLP, Zheijang Daji Medical Instruments, Ltd., Nimble International, AME Line, Technico, Cepeo, Contraceptivos, Injeflex Ind And Com Ltda, Bersil, Amed among others holds 34.0% of the IUCD delivery market in 2016.
BAYER HEALTHCARE AG
Founded in 1863 and headquartered in Leverkusen, Germany, Bayer AG is a provider of healthcare, nutrition, and high-technology materials and services. The company has three business segments, namely, HealthCare, Crop Science, and Material Science. The HealthCare segment offers a wide range of products under animal health, pharmaceuticals, consumer care, and medical care. The pharmaceutical business offers a wide range of products in the therapeutic area of oncology, haematology, and ophthalmology, and offers products for women’s health and cardiology therapeutic applications.
1. In October 2016, Bayer AG has successfully concluded the European registration procedure to gain EUwide marketing authorization for its new low-dose levonorgestrel-releasing intrauterine system (LNGIUS). The product is named Kyleena and will be available in the market from 2017 January.
2. In September 2016, Bayer AG has successfully received FDA approval for its new low-dose levonorgestrel releasing intrauterine system (LNG-IUS) “Kyleena” The launch of this product in October in U.S.
Inquiry for TOC Visit @ databridgemarketresearch.com/toc/?dbmr=global-intra-uteri...
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Established in 1901 and headquartered in Petah Tikva, Israel, Teva is one of the leading global companies in IUCD devices market. The company is engaged in developing, producing, and marketing affordable generic drugs as well as innovative and specialty pharmaceutical ingredients. Teva operates through two business segments, namely generic medicine and specialty medicine. Teva's specialty medicines business focuses on central nervous system (CNS), respiratory oncology, pain, and women's health therapeutic areas as well as biologics.
MONA LISA N.V.:
Mona Lisa N.V. was founded in 1996, and is a subsidiary for Eurim Pharma headquarterd in Germany. Prior to 1996 the company was known as Homesteel-Achel which was an exclusive sub-manufacturer for Organon from 1980 to 1996. Mona Lisa specializes in manufacturing class II and III medical devices used in the field of gynecology. Mona Lisa N.V products are Copper-Intrauterine-Devices (IUD), Aspiration needles and Consultation services / sub-manufacturing services.
View Full Report Visit @ databridgemarketresearch.com/reports/global-intra-uterine...
Global Tumour Ablation Market – Trends and Forecast to 2024
Global Tumour Ablation Market, By Type (Tumour Ablation Systems (Radio Frequency Ablation, Microwave Ablation, HIFU, Laser Ablation, Cryoablation), Image Guidance Products, Accessories), By Cancer Type (Liver, Lings, Kidney, Brain, Bone, Pancreas, Breast, Others), By End-User (Hospitals, Oncology Clinics, Others), By Geography (North America, South America, Europe, Asia-Pacific, Rest of the World) – Trends and Forecast to 2024
Report Access: databridgemarketresearch.com/reports/global-tumour-ablati...
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge Market Research
Visit Blog: databridgemarketresearch.com/blog/
Follow us on LinkedIn: www.linkedin.com/company/data-bridge-market-research
This release was published on openPR.
News-ID: 897429 • Views: 392More releases